OSS, NETHERLANDS – December 11th, 2019 – APO-T B.V. announced today the expansion of its Scientific Advisory Board (SAB) with the addition of dr Michael Saunders and dr Torsten Dreier.
Dr Saunders joined Ablynx NV in 2006 as an independent consultant and led the successful Nanobody Landgrab program selecting 100 therapeutic targets and identifying nanobodies of therapeutic relevance against these targets. Within Ablynx, dr Saunders led also an external program as Alliance Manager with Boehringer Ingelheim, in parallel to internal drug discovery programs. At arGEN-X BVBA, which he joined in 2009 as Senior Director Targets and Programs, and later became VP External Research, he contributed to the discovery of six antibodies (in clinical and preclinical development). At arGEN-X BVBA he played an important role in establishment and maintenance of academic collaborations and Alliance Management with Pharma partners such as Shire, Bayer or Eli Lilly, and later led the Innovative Access Program. Dr Saunders holds a PhD in Biology from the University North Carolina, USA and undertook postdoctoral training in the laboratory of Professor Pierre Chambon in Strasbourg, France, before working for 9 years with GSK on small molecule drug discovery. He also received general management training (EMBA) at ESSEC (France) and Mannheim Business School (Germany).
Dr Dreier joined Micromet AG in Munich, Germany in 1997, where he later became Director Preclinical Development and headed the preclinical characterization of recombinant antibodies and bispecific T cell engagers (BiTEs). These efforts ultimately led to approval of the first bispecific T cell engager being currently the only bispecific antibody, which obtained marketing authorization, namely Blinatumomab (approved for the treatment of ALL). Between 2003 and 2008 dr Dreier served as Director of Therapeutic Drug Development and Senior Director Preclinical Development at Ablynx NV. During this time, dr Dreier, amongst other projects, progressed Caplacizumab to clinical development, a drug which obtained marketing authorization by the FDA in TTP in 2019. Dr Dreier co-founded arGEN-X BVBA and served as Chief Development Officer for 11 years, in which he progressed 6 development candidates into clinical development. Dr Dreier holds a PhD in Biochemistry from the University of Tübingen, Germany and undertook postdoctoral training in the group of Professor Ralph Reisfeld at the Scripps Research Institute in La Jolla, CA.
“We are pleased to expand our Scientific Advisory Board with the addition of dr Saunders and dr Dreier,” said dr Marta Kijanka, acting CEO of APO-T. “Dr Saunders and dr Dreier each bring in more than 20 years of highly relevant experience in the field of antibody-based therapeutics. Their advice will be invaluable in advancing our pre-clinical programs to clinical stage.” “I am excited to join the SAB of APO-T, biotech company which strives to provide cancer patients with so urgently needed innovative therapy allowing for removal of the transformed cells while maintaining quality of life.” said dr Dreier. Dr Saunders added: “APO-T employs a unique approach, by targeting tumor cells with antibodies specific to an intracellular tumor marker. The tumor target chosen by APO-T, expressed across various, histologically different tumors, not only contributes to the safety benefit, but importantly provides opportunity for treatment continuation when escape occurs.”
About APO-T BV Netherlands-based APO-T B.V., a pre-clinical stage biotech company, develops antibody-based therapeutics targeting intracellular tumor marker, i.e. MAGE, when presented by MHC-I exclusively on the surface of tumor cells.
For further inquiries:
Marta Kijanka PhD, acting CEO
5349 AB, Oss
T: +31 (0)85 13 00 529